Abbott announced on 2 April that it has received US Food and Drug Administration approval to market its TriClip G4 system for repairing a leaky tricuspid valve, a condition that the company says affects about 1.6 million people in the US.
The approval comes after a 13 February meeting of the FDA’s circulatory system panel endorsed TriClip G4 for treating severe...






